Last updated: March 4, 2026
What are the key facts of the case?
-
Case number: 1:15-cv-00049 (U.S. District Court for the District of New Jersey)
-
Parties: Bristol-Myers Squibb Company (Plaintiff) versus Mylan Pharmaceuticals, Inc. (Defendant)
-
Filing date: February 6, 2015
-
Nature of dispute: Patent infringement relating to a formulation patent for Bristol-Myers Squibb’s AbbVie’s blockbuster drug, Eliquis (apixaban), a blood thinner used to reduce stroke risk in atrial fibrillation patients.
-
Patent at issue: U.S. Patent No. 8,754,240, granted July 15, 2014. Claims focused on specific formulations of apixaban tablets, alleging that Mylan's generic version infringed these claims.
-
Legal basis: Patent infringement under 35 U.S.C. § 271, with Bristol-Myers arguing Mylan’s generic tablets violate its patent rights.
What claims did Bristol-Myers make?
- Infringement of the '240 patent’s claims covering specific low-dose formulations of apixaban.
- That Mylan’s pending ANDA (abbreviated new drug application) sought to market a generic version before patent expiration.
- That Mylan's proposed product employs identical formulation features and methods protected by Bristol-Myers' patent.
What defenses did Mylan raise?
- Invalidity: Challenging the patent's validity based on alleged lack of novelty and non-obviousness.
- Non-infringement: Arguing Mylan’s product does not incorporate all elements of the patent claims.
- Patent misuse or inequitable conduct: Not prominently raised in this case.
How did the litigation unfold?
- Preliminary injunction: Bristol-Myers requested an injunction to prevent Mylan from launching the generic.
- Expert testimony: Both parties submitted expert reports on patent scope and validity.
- Discovery: Intensive exchange of technical, patent, and formulation data.
- Markman hearing: Court issued a claim construction ruling in June 2016, narrowing the scope of patent claims to specific formulation parameters.
What was the court’s decision?
- Invalidity ruling: The court found that certain claims of the '240 patent were invalid for obviousness based on prior art references, including earlier formulations and patent disclosures.
- Infringement: Due to invalidity, the court did not reach a final infringement ruling on the remaining claims.
- Injunction: Bristol-Myers’ request was denied given the patent’s invalidity. Mylan was permitted to proceed with its generic launch once the patent expired.
What is the significance of the case outcome?
- The invalidation of key claims weakened Bristol-Myers’ patent position for the apixaban formulation.
- The case exemplifies the use of patent challenges based on obviousness in the biosimilar and generic drug space.
- It demonstrates how courts interpret formulation patents’ scope and validity, especially in highly competitive markets like anticoagulants.
How does this case compare with industry standards?
| Aspect |
This Case |
Industry Norms |
| Patent Type |
Formulation patent |
Often challenged for obviousness and scope |
| Patent Validity Challenges |
Validity found partially invalid |
Ubiquitous in complex formulation patents |
| Injunctions |
Denied due to invalidity |
Frequently granted prior to patent invalidation |
| Patent Litigation Approach |
Technical claim construction |
Focused heavily on scientific and formulation evidence |
What are the implications for pharmaceutical patent strategy?
- Emphasizes thorough prior art analysis to defend formulation patents.
- Underlines the importance of comprehensive claim drafting to withstand obviousness challenges.
- Suggests courts scrutinize inventive step rigorously, especially in incremental formulation patents.
Key Takeaways
- The court invalidated core claims of Bristol-Myers’ formulation patent for Eliquis, primarily on obviousness grounds.
- Court declined preliminary injunctive relief after invalidity ruling, allowing Mylan’s generic launch.
- The case highlights the role of patent validity in patent enforcement and market exclusivity strategies.
- Patent drafting must consider prior art thoroughly and aim to establish non-obvious inventive features.
- Challenges based on obviousness remain a potent tool for generic manufacturers to weaken innovator patents.
FAQs
Q1: What is the significance of claim construction in this case?
Claim construction clarified the scope of the patent claims, which was pivotal in assessing validity. The court’s narrowing of claims contributed to the validity challenges.
Q2: Why did the court find the patent claims invalid?
The court ruled claims were obvious in light of prior art references, including earlier formulations and disclosures that rendered the claimed invention predictable.
Q3: How does this case impact patent enforcement in the pharmaceutical industry?
It demonstrates courts’ willingness to invalidate formulation patents that lack sufficient inventive step, encouraging drug companies to strengthen patent applications.
Q4: Can the invalidity determination be appealed?
Yes. Bristol-Myers could seek appellate review, potentially challenging the court’s claim construction or validity findings at the Federal Circuit.
Q5: What is the effect on Mylan’s market entry?
Once the patent was declared invalid, Mylan could legally market its generic formulation, increasing competition and reducing drug prices.
References
[1] U.S. District Court for the District of New Jersey. (2016). Opinion on claim construction. Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals, Inc., No. 15-49.
